ScreenerHero

INBXInhibrx, Inc.

NAS · US · Healthcare · Biotechnology · inhibrx.com
103.63USD+2.12%Mkt Cap: 1.53B $P/E: —

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.53B $
Enterprise Value1.51B $
Revenue (TTM)0 $
Gross Profit-103.00M $
Net Income (TTM)-140.06M $
Revenue/Share0.0000 USD
Last Price103.63 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees109
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.74
PEG—
EV/EBITDA-12.00
EV/Revenue—
P/SInfinity
P/B-27.53
EPS (TTM)-8.66
EPS (Forward)-6.30
52W Range
22.4061% of range155.29
52W High155.29 USD
52W Low22.40 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-10773.46%
ROE-1752.22%
ROA-95.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-129.79M $
CapEx (TTM)31.00K $
FCF Margin—
FCF Yield-5.58%
Net Debt48.28M $
Net Debt/EBITDA-0.38
Balance Sheet
Debt/Equity13.39
Current Ratio5.07
Quick Ratio4.76
Book Value/Sh-3.6020 USD
Cash/Share9.060 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)277.50 USD
Upside (mean)+167.8%
Target Range230.00 USD – 325.00 USD
$230.00+167.8% to mean$325.00
# Analysts2
Ownership
Shares Out.14.72M
Float8.64M
Insiders23.08%
Institutions91.02%
Short Interest
Short Ratio11.6d
Short % Float30.44%
Short % Out.22.77%
Shares Short3.34M
Short (prev mo.)3.45M
Technical
SMA 5091.23 (+13.6%)
SMA 20086.69 (+19.5%)
Beta3.52
S&P 52W Chg18.16%
Avg Vol (30d)232.82K
Avg Vol (10d)288.80K
Technical Indicators
RSI (14)64.3
MACD2.2760
MACD Signal0.2212
MACD Hist.+2.0548
BB Upper102.92 USD
BB Middle88.28 USD
BB Lower73.64 USD
BB Width33.16%
ATR (14)6.441 USD
Vol Ratio (20d)1.09x